https://www.thebodypro.com/category/hiv-epidemiology/tag/conference-coverage
HIV Epidemiology

Conference Coverage

The Latest

Elvitegravir in Children and Adolescents Img

Elvitegravir in Children and Adolescents

Three posters at CROI 2015 showed new pediatric elvitegravir data. The posters described preliminary safety in the 6-to-12-year-old age group, and safety, efficacy, pharmacokinetics and resistance in 12-to-18 year olds receiving elvitegravir in fixed...

Advocates for Women Talk About CROI 2015 Img

Advocates for Women Talk About CROI 2015

A webinar co-sponsored by The Well Project, Positive Women's Network-USA and TheBody.com/TheBodyPRO.com draws attention to data of interest to women with HIV, their care providers and those interested in HIV prevention for women.

3-Drug Antiretroviral Therapy Best for Preventing Vertical Transmission to Infants: Results From the PROMISE Study Img

3-Drug Antiretroviral Therapy Best for Preventing Vertical Transmission to Infants: Results From the PROMISE Study

Taking a three-drug antiretroviral therapy combination in pregnancy was more effective in preventing mother-to-child transmission than taking one drug during pregnancy, another in labor and two after delivery.

Lopinavir/Ritonavir Superior to Nevirapine in Children Over 3 Years Old: IMPAACT P1060 Study Results Img

Lopinavir/Ritonavir Superior to Nevirapine in Children Over 3 Years Old: IMPAACT P1060 Study Results

Long-term virologic suppression was superior in children receiving lopinavir/ritonavir-based antiretroviral therapy compared with nevirapine-based regimens at five-year follow up in the IMPAACT P1060 trial.

Point of Care HIV PCR Test for Infant Diagnosis: Good Performance but Poorer Results in Youngest Age Group Img

Point of Care HIV PCR Test for Infant Diagnosis: Good Performance but Poorer Results in Youngest Age Group

A point of care (POC) assay performed well in infant diagnosis in a large laboratory study. But its error rate of 6% has implications for implementation and its newborn performance requires further evaluation.

Long-Term Safety and Efficacy of Tenofovir in Children Img

Long-Term Safety and Efficacy of Tenofovir in Children

Tenofovir was well tolerated in children for up to 336 weeks, according to preliminary efficacy and safety data presented at CROI 2015.

HIV Transmission Risk Remains During First 6 Months of Treatment Img

HIV Transmission Risk Remains During First 6 Months of Treatment

A person living with HIV can transmit the virus during the first six months of starting treatment. Researchers suggest extra prevention strategies for mixed-status couples during this period before viral suppression is achieved.

How Marijuana Use Affects HIV Testing and Care Img

How Marijuana Use Affects HIV Testing and Care

Smoking marijuana was associated with less HIV testing, but didn't affect a patient's journey toward viral suppression, according to a study presented at CROI 2015.

Biggest HIV Developments From CROI Over the Past 3 Years Img

Biggest HIV Developments From CROI Over the Past 3 Years

Let's take a look back to see why CROI has proven to be a groundbreaking conference in recent years.

Promo Image

HIV Researchers Weigh In on Ebola Outbreak

With the Ebola outbreak making headlines, many have drawn comparisons to the early days of the AIDS epidemic. We asked HIV researchers and clinicians what their opinions were on the current Ebola epidemic.